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Abstract 
 
The second MURIA (Medicines Utilisation Research in Africa) group workshop and symposium again 
brought researchers together from across Africa to improve their knowledge of drug utilisation (DU) 
methodologies and exchange ideas to further progress DU research in Africa. This built on extensive 
activities since the first conference including workshops and multiple publications. Anti-infectives were 
again the principal theme for the 2016 symposium following the workshops. This included 
presentations regarding strategies to improve antibiotic utilisation among African countries such as 
point prevalence studies as well as potential ways to reduce self-purchasing of antibiotics. There were 
2 
 
also presentations on ARVs including renal function and the impact of policy changes. Concerns with 
adherence to chronic treatments as well as drug: drug interactions and their implications were also 
discussed. The deliberations resulted in a number of agreed activities before the next conference in 
Namibia in 2017. 
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Manuscript 
 
MURIA is a multidisciplinary research group striving to promote sustainable, rational medicine use in 
Africa (1). Activities include the first MURIA meeting in July 2015, activities to improve antibiotic 
utilisation in Africa (2) and the second MURIA meeting - 25th to 27th July 2016. This was opened by 
DVCAA University of Botswana (Professor Mokgwathi), who emphasised the importance of MURIA 
meetings including enhancing the appropriate use of anti-infectives and the training of young 
scientists to carry out future research. 
 
Delegates subsequently attended either introductory or advanced workshops. Margaret Oluka and 
Ilse Truter opened the Introductory Drug Utilisation (DU) workshop. Key issues included definitions 
and classifications, types of DU research, data sources and examples. This was followed by 
discussions concerning qualitative research applied to DU studies. Key characteristics include its 
purpose, primary instruments for data collection, inductive process to gather evidence and the 
product, i.e. the descriptive data. Finally, Marike Cockeran gave a comprehensive workshop on the 
introduction to statistical techniques applied to DU research.  
 
The advanced workshop was divided into four sessions, two in the morning and two in the afternoon. 
Marike Cockeran and Michael Law presented the first workshop on advanced statistics including 
discussions on multilevel models and interrupted time series analyses. Both included examples. The 
second morning workshop focused on developing formularies and DTCs. Lars Gustafsson discussed 
the need and role for DTCs illustrated by the µWise List¶ with high adherence rates, driven by robust 
principles, physician trust and active dissemination (3, 4). Kidwell Matshotyana discussed MSH 
support for developing DTCs including the development of Standard Treatment Guidelines (STGs) in 
Swaziland (5). Joseph Fadare presented preliminary results of a survey of DTC activities in Nigeria, 
suggesting a lack of DTCs in many healthcare facilities and often sub-optimal functioning where these 
exist. Brighid Malone discussed the development of the Bokamoso antibiotic guideline including 
restricted antibiotics as well as the Antimicrobial Stewardship (AMS) programme. 
 
Andy Gray discussed ways to strengthen research protocols and proposal writing in the afternoon 
workshops. The other afternoon workshop centred on national and cross national comparative (CNC) 
studies. Olayinka Ogunleye discussed the challenges of undertaking studies in Nigeria including 
unrestricted availability of medicines and a lack of coordinated pharmaceutical policies. However 
there are positive changes including coordinated research published and presented at MURIA 
conferences (6, 7). Lars Gustafsson discussed the efavirenz (EFV) studies in Uganda, already 
resulting in publications (8). Strengths included utilization of different expertise, expanding 
collaborations as well as learning more about EFV among African patients, which is a concern (9). 
Brian Godman finished by discussing lessons learnt from European CNC studies including health 
authorities learning from the launch of generics as witnessed by the speed of their response to 
generic ARBs compared with earlier generics (10, 11).  
 
The workshops were followed by presentations on antibiotic research in Botswana. Matshediso 
Matome discussed planned research on the management of URTIs among private GPs in Botswana 
as they are a critical point for dispensing antibiotics and antibiotics being the most dispensed 
medicines. Utlwang Toko discussed the AMS programme in Bokamoso hospital among ICU patients, 
including daily visits from pharmacists as well as implementation of the hospital antibiotic guidelines. 
Charles Jolomba discussed the AMS programme in Gaborone Private Hospital including reviewing 7 
aspects of care such as appropriate dosing, step down from IV to oral and  <4 antimicrobial 
prescribed in a given patient. Total bundle compliance was 77.4% over a 12 month period. Bene 
Anand Paramadhas finished by discussing the results of the pilot point prevalence study (PPS) 
initiated following the February 2016 meeting (1). Key points included a high percentage with HIV and 
treated with HAART (over 90% in the District Hospital) as well as concerns with the high prevalence 
of 2 or more catheters.  
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Margaret Oluka subsequently discussed ongoing programmes in Kenya to reduce AMR, including 
optimising antibiotic use and investing in R & D, educational initiatives, surveillance research and 
antibiotic DU studies. Hannelie Myer discussed planned programmes among public hospitals in South 
Africa including a planned PPS study, building on activities in Botswana (2). Romuald Mbwasi 
discussed ongoing programmes in Tanzania including the development of a National multi-sectoral 
AMR committee. Draft AMR policies have been developed aiming for completion by the end of 
September 2016. Finally, Sekesai Zinyowera discussed ongoing activities in Zimbabwe including the 
findings from a recent KAP study, which showed a high number of antibiotics prescribed per patient, 
exacerbated by patient expectations and physician fears. There were also fears of AMR among 
pharmacists although over 40% admitted dispensing without a prescription, the most common reason 
being the unaffordability of a physician visit.  
 
General DU research in Tanzania included ascertaining drug prescribing in two hospitals in Mwanza 
(12). Kidwell Matshotyana compared selected prescribing indicators measured before and after the 
implementation of STGs in Swaziland. Their implementation had a positive but a small level impact on 
prescribing patterns including reducing the average number of medicines per encounter, reducing 
physician encounters ending with an antibiotic, reducing the number of injections prescribed and 
improving STG availability. 
 
Dan Kibbule started the abstract presentations by discussing policies for cotrimoxazole, amoxicillin 
and azithromycin (CAA) LQ1DPLELD¶VSublic sector. There are concerns that existing policies promote 
their wide use. As a result, calls for the development of more comprehensive antibiotic guidelines that 
are in tandem with AMR patterns. Aubrey Kalungia discussed the prevalence of non-prescription 
sales and dispensing of antibiotics in community pharmacies in Zambia despite laws forbidding this 
(13). Dispensing was more prevalent among pharmacy technicians than pharmacists. Sajini Souda 
presented findings on infant cotrimoxazole (CTX) prophylaxis and found no statistically significant 
difference in diarrheal disease, pneumonia or death comparing infants with resistant commensal 
organisms versus sensitive commensal organism. Consequently, concerns that CTX prophylaxis may 
outweigh the benefits. Francis Kalemerra discussed the effect of changing from first- to second- line 
antiretroviral therapy on renal function based on his recent paper (14). Michael Law finished this 
session discussing the impact on ARV use after Rwanda changed the threshold for treatment from 
CD4 < 350 to < 500. This change transiently increased treatment initiation; however, it did not have a 
major impact on overall treatment rates.  
 
Mwangana Mubita subsequently described the effect of different renal function assessment methods 
RQWHQRIRYLU¶VVDIHW\UHSRUts. There was a significant lack of agreement between the Cockcroft-Gault 
(C-G) method and the Chronic Kidney Disease-Epidemiology method, with the C-G method 
potentially reporting more cases of TDF-associated renal impairment. Consequently, this method 
should be re-considered. Margaret Oluka discussed ADRs to ARVs. Nevirapine based regimens still 
the most common for ADRs, with  women still bearing the brunt of HIV and ADRs in Kenya similar to 
other African countries (9). Overall, there is a successful National pharmacovigilance (PV) system in 
Kenya but the quality of spontaneous reports could be improved.  Antionette Terblanché discussed 
baseline data for the development and evaluation of a structured PV system in Sebokeng Hospital, 
South Africa. The majority (96.2%) of professionals felt it necessary to report ADRs, however only a 
minority did. The most common reason was not knowing how, where and when to report. 
Consequently, training for professionals should be improved and reporting forms made easily 
accessible. Adetutu Ajemigbitse discussed the outcome of an intervention to reduce prescribing errors 
among tertiary hospitals in Nigeria. Pharmacist-led interventions produced some success. However, 
the sum effect was not statistically significant. Bene Anand Paramadhas discussed initiatives on 
medication safety at Nyangabgwe hospital in Botswana. The Pharmacy department chose an Annual 
Performance Objective of reducing the incidence of actual medication errors to < 1 per 100,000 items 
dispensed helped by an independent double check system. Recent programmes appreciably reduced 
the number of actual errors reaching the patient to 1.85% of potential errors. Bayobuya Phulu finished 
Day 2 by discussing ways to promote RUM through active DTCs in Namibia including DTC training, 
regular ward visits as well as prescriber training on STGs. 
 
Day 3 started with a tribute to Matthias Adorka, MURIA initiator (1), from the Pharmacy Team at the 
University of Namibia following his untimely death . Mary Jande subsequently discussed adherence 
rates to antihypertensive among patients attending clinics in Tanzania, which were low compared to 
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the UHTXLUHGOHYHORI(ducational initiatives are needed to address concerns. Martie Lubbe 
subsequently discussed medicine possession ratios (MPRm) as proxy for adherence to antiepileptic 
drugs (AEDs). )XUWKHUUHVHDUFKLVQHHGHGWRGHWHUPLQHWKHIDFWRUVLQIOXHQFLQJHSLOHSWLFSDWLHQWV¶low 
prescription refill adherence rates. Johanita Burger discussed methods to detect potentially serious 
drug-drug interactions XVLQJWKH0DWDQRYLü9ODKRYLü-3DOþHYVNLGUXJ-drug interaction protocol as no 
established protocols for African patients. Johanita concluded this tool might be a useful initial 
screening tool to prevent the most common potentially serious drug-drug interactions. Ilse Truter 
discussed vaccination coverage in underprivileged Grade-R school children in Nelson Mandela Bay 
Health District. Coverage was lower than the average coverage for the Eastern Cape, with a trend 
linking stunting to incomplete vaccination schedules.  Godfrey Rwegerera discussed anti-diabetic 
medication adherence rates in a tertiary referral centre in Botswana. Overall, adherence rates were 
suboptimal, mirroring other studies.  Only HIV positivity was significantly associated with better 
medication adherence. Finally, Olayinka Ogunleye presented the results of the African Pharmacology 
Science Gateway (APSG)/ MURIA survey regarding $IULFDQ5HVHDUFKHUV¶needs to guide discussions 
on next steps. Key pertinent areas included continued training in DU and statistics, prescription 
databases, establishment of PV centres, greater collaboration/ networks and continued funding for 
conferences. These themes were taken forward and discussed as part of proposed activities for 2016/ 
207. All abstracts and workshop presentations can be found on the MURIA website as well as 
membership forms (http://muria.nmmu.ac.za/). 
 
The feedback from the meeting was positive with attendees typically finding workshop presenters 
knowledgeable in their areas (4.47 out of 5), the content relevant to their needs and could be applied 
to their workplace (4.57). Similarly for the symposium at 4.43 and 4.49.The main criticism was not 
enough time to debate key issues (3.87). We look forward to the third MURIA Group meeting in 
Namibia in July 2017. 
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